Samsung Epis Holdings said on the 23rd that operating profit at its subsidiary Samsung Bioepis for the first quarter rose 13% from a year earlier to 144.0 billion won. Revenue for the period increased 14% to 454.9 billion won.
The company said broader sales of global biosimilar products and the expansion of new product lines drove earnings growth. In addition to stable revenue from existing products, successive launches of new products in the United States and Europe translated into results through tailored strategies by region and product.
Samsung Bioepis directly sells a total of four biosimilars in Europe. While existing products such as the Enbrel biosimilar "SB4" maintain solid sales, the Eylea biosimilar "SB15" is set to launch in Europe and the United States.
In the United States, the Prolia biosimilar "SB16" launched on Jan. 1. The product signed a private-label supply agreement with CVS Caremark and was added to its preferred drug list, focusing on expanding market share.
It is also working to secure follow-on pipeline assets. In March, Samsung Bioepis signed an initial collaboration agreement with Switzerland's Sandoz for the development of the Entyvio biosimilar "SB36." The strategy is to participate jointly from the early development stage to raise the likelihood of commercialization.
New drug development is also underway. The antibody-drug conjugate (ADC)-based drug candidate "SBE303" entered global Phase 1 in March this year, and preclinical results were recently presented at the American Association for Cancer Research (AACR 2026). Another candidate, "SBE313," is in the preclinical stage.
The holding company, Samsung Epis Holdings, posted 453.9 billion won in revenue and 90.5 billion won in operating profit on a consolidation basis. It is the first quarterly profit since its launch in November last year. The company said results improved despite non-cash accounting factors.